



**AMD L Contact:**  
Kristine Szarkowitz  
Director-Investor Relations  
[kszarkowitz@radient-pharma.com](mailto:kszarkowitz@radient-pharma.com)  
(Tel :) 206.310.5323

**FOR IMMEDIATE RELEASE**

## **RADIANT PHARMACEUTICALS FILES EXTENSION FOR THIRD QUARTER 2009 FINANCIAL RESULTS**

**(TUSTIN, CA) November 16, 2009/PRNewswire** – Radiant Pharmaceuticals Corporation (NYSE - AMEX: [RPC](#) - [News](#)), a US-based pharmaceutical company, announced today it has filed a Notification of Late Filing under Rule 12b-25 of the Securities Exchange Act of 1934, as amended, with the Securities and Exchange Commission (the "SEC") for its Quarterly Report on Form 10-Q for the third quarter ended September 30, 2009.

This filing provides for an extension for the filing of its Quarterly Report on Form 10-Q until November 23, 2009. The Company's Quarterly Report on Form 10-Q for the nine months ended September 30, 2009, could not be filed within the prescribed period because the Company was unable to compile certain information required in order to permit the Company to file a timely and accurate report on the Company's financial condition. This inability could not have been eliminated by the Company without unreasonable effort or expense. We expect to file the Quarterly Report within the allotted time. For additional information contact Radiant Pharmaceutical Corporation's Investor Relations at 206.310.5323.

### **About Radiant Pharma:**

Headquartered in Tustin, California, Radiant Pharmaceuticals Corporation is an integrated pharmaceutical company devoted to the research, development, manufacturing, and marketing of diagnostic, and premium skin care products.

### **Forward Looking Statements:**

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: The statements contained in this document include certain predictions and projections that may be considered forward-looking statements under securities law. These statements involve a number of important risks and uncertainties that could cause actual results to differ materially including, but not limited to, the performance of joint venture partners, as well as other economic, competitive and technological factors involving the Company's operations, markets, services, products, and prices. With respect to Radiant Pharmaceuticals Corporation, except for the historical information contained herein, the matters discussed in this document are forward-looking statements involving risks and uncertainties that could cause actual results to differ materially from those in such forward-looking statements.

**###**